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ABSTRACT 
 
Background: Inflammation influences cancer development and progression. An 
elevated platelet/lymphocyte ratio (PLR), a marker of inflammation, has been linked 
to poor prognosis in several malignancies. Here we quantify the prognostic impact of 
this biomarker. 
Methods: A systematic review of databases was conducted to identify publications 
exploring the association of blood PLR and overall survival (OS) in solid tumors. 
Data were pooled in a meta-analysis. Pooled HRs for OS by disease group and by 
PLR cut-off groups were computed and weighted using generic inverse-variance and 
random-effect modeling. 
Results: Twenty studies comprising 12,754 patients were assessed. Cut-offs for PLR 
defining risk groups ranged from 150 to 300 and were dichotomous (12 studies, 
[group 1]) or split into 3 groups (<150/150-300/>300, 8 studies, [group 2]). Higher 
PLR was associated with significantly worse OS in group 1 (HR=1.87; 95%CI: 1.49-
2.34, P<0.001) and with a non-significant association in group 2 (HR per higher 
category=1.21, 95%CI: 0.97-1.50; P=0.10). The size of effect of PLR on OS was 
greater for metastatic disease (HR[group 1]=2.0, 95%CI: 1.6-2.7; HR[group 2]=1.6, 95%CI: 
1.1-2.4)  than for early stage disease (HR[group 1]=1.5, 95%CI: 1.0-2.2; HR[group 2]=1.0, 
95%CI: 0.8-1.3). A significant association was observed for colorectal, 
hepatocellular, gastroesophageal, ovarian, and pancreatic carcinoma in group 1 and 
for colorectal cancers in group 2. 
Conclusion: A high PLR is associated with worse OS in various solid tumors. Further 
research of its regulation and relevance in daily practice is warranted. 
Impact: PLR is a readily available and inexpensive biomarker with independent 
prognostic value in solid tumors.  
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Introduction 
 
 Inflammation is a hallmark of cancer (1) and there is often a complex host-
tumor relationship with most tumors having inflammatory cells and mediators present 
in their microenvironment (2, 3). A variety of oncogenes, tumor secreted factors and 
cytokines secreted by inflammatory cells can lead to the recruitment of inflammatory 
mediators (3). Based on these findings, a variety of markers of inflammation have 
been investigated for association with cancer progression and prognosis (4).  
  White cell and neutrophil counts, elevated C-reactive protein (CRP) and 
hypoalbuminemia are the biochemical parameters associated with a systemic 
inflammatory response that are evaluated most often (4). Several of these parameters 
have been converted to ratios or prognostic scores such as the Glasgow Prognostic 
Score (GPS, incorporating CRP and albumin) (5) or the neutrophil to lymphocyte 
ratio (NLR) (6). Platelets are also part of the inflammatory response and 
thrombocytosis is common in patients with solid tumors (7, 8). Platelets are known to 
interact with tumor cells directly and to contain factors that contribute to tumor 
growth, invasion and angiogenesis (9). Platelets can protect tumor cells from NK-cell 
mediated lysis, thereby facilitating metastasis (10). The link between thrombocytosis, 
poor prognosis and shorter survival time has been established in several types of solid 
tumors including breast, lung, colon, gastric, and ovarian cancer (11). This is thought 
to occur due to thrombopoietic cytokines such as interleukin 6 (IL-6) being secreted 
by tumor cells (11). With the recognition that low lymphocyte counts may also be 
associated with shorter survival (12), the platelet to lymphocyte ratio (PLR) has been 
studied as a prognostic biomarker. It has been hypothesized that an increased PLR is 
indicative of an increased host inflammatory response associated with more 
aggressive tumor characteristics (13).  
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The aim of the present study was to review the literature investigating the 
association of peripheral blood PLR in solid tumors with overall survival (OS) and to 
combine the results in a meta-analysis. Our hypothesis was that high PLR correlates 
with worse OS and may thus serve as a readily available and inexpensive prognostic 
marker in both clinical practice and for the stratification of patients in clinical trials.  
 
 
Materials and Methods 
 
 This analysis was conducted in line with guidelines for the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (14). 
 
Data sources and searches 
 An electronic search of the following databases was undertaken: Medline 
(host: OVID) from 1946 to June 2013, EMBASE (host: OVID) from 1974 to June 
2013, Cochrane Database of Systematic Reviews from 2005 to June 2013. Manual 
searches were undertaken for abstracts presented at meetings of the American Society 
of Clinical Oncology (ASCO) from 2011 to 2013, and the European Society of 
Medical Oncology (ESMO) from 2011 and 2012 (it was assumed that abstracts 
presented earlier would be captured as fully published papers). Search terms included 
cancer, platelets, lymphocytes and ratio. Citation lists of retrieved articles were 
screened to ensure sensitivity of the search strategy. The full search strategies are 
described in Supplementary Material, available online.  
 
Study selection 
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 Inclusion criteria were: (i) studies in solid tumors reporting the prognostic 
impact of the peripheral blood PLR, (ii) assessment of PLR by cut-off into different 
risk strata, and (iii) availability of a hazard ratio (HR) for OS or Kaplan Meier 
survival curves from which it could be calculated. Duplicate publications were 
excluded and for the main analysis so were studies that reported PLR as a continuous 
variable. Two reviewers (AT, MMN) evaluated independently all the titles identified 
by the search strategy. Inter-reviewer agreement was assessed using Cohen’s kappa. 
Disagreement was resolved by consensus. The results were then pooled and all 
potentially relevant publications retrieved in full and assessed for eligibility. 
Corresponding authors were contacted to clarify any missing or ambiguous data.  
 
Endpoints of interest 
 Survival based on high versus low PLR was the primary outcome of interest. 
In exploratory analyses we compared the relative prognostic impact of PLR with 
other markers of inflammation, namely the neutrophil to lymphocyte ratio (NLR), C-
reactive protein (CRP), and the Glasgow Prognostic Score (GPS) or modified 
Glasgow Prognostic Score (mGPS). 
  
Data extraction 
 Data were collected using predesigned abstraction forms. The following 
details were extracted: Name of first author, type of publication (abstract or full text), 
year of publication, journal, number of patients included in study, disease site, disease 
stage (non-metastatic, metastatic or mixed [i.e. non-metastatic and metastatic]), 
collection of data (prospective or retrospective), cut-off used to define high peripheral 
blood platelet to lymphocyte ratio (PLR), receiver operating characteristic (ROC) 
curves considered for selection of cut-off (yes or no), and HR for OS with associated 
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95% confidence intervals (CI) or P-value. If information about OS was not available, 
data for cancer-specific survival (CSS) was captured with the assumption that most 
deaths would be disease related. HRs were extracted from multivariable analyses 
where available. Otherwise, HRs from univariable analyses were extracted or 
estimated from Kaplan Meier survival curves as described by Parmar et al. (15). 
Whenever available, HRs for survival associated with NLR, CRP and GPS/mGPS 
were also collected. To evaluate the relative prognostic impact of PLR with these 
other markers of inflammation, HRs for subgroups defined by different markers were 
compared. 
 
Data synthesis and statistical analyses 
 Study quality was assessed based on control for confounding factors. 
Specifically, good quality studies were defined as those, which explicitly reported that 
patients with baseline infectious or inflammatory conditions were excluded form the 
analysis and where assessment of PLR was undertaken prior to treatment (surgery, 
systemic therapy or radiation). Extracted data were combined into a meta-analysis 
using RevMan 5.2 analysis software (Cochrane Collaboration, Copenhagen, 
Denmark). Estimates of HRs were weighted and pooled using the generic inverse 
variance and random-effect model. Analyses were conducted separately for studies 
using dichotomous groups and for three groups to define high versus low PLR. 
Subgroup analyses were also conducted based on disease site and disease stage. 
Statistical heterogeneity was assessed using Cochran’s Q and I2 statistics. Differences 
between the reported HR for subgroups defined by different inflammatory markers 
reported in individual studies were also assessed. Sensitivity analyses was performed 
using methods described by Deeks et al. (16). Publication bias was assessed with 
visual inspection of funnel plots. Meta-regression analysis was performed to evaluate 
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the effect of study quality on the HR for OS. All statistical tests were two-sided, and 
statistical significance was defined as P< 0.05. No correction was made for multiple 
testing.  
 
 
Results 
 
Included studies 
 A total of 22 studies were identified (Figure 1). Cohen’s kappa for inter-
reviewer agreement for paper selection was 0.78 (95% CI 0.63 – 0.88).  Studies 
included a total of 12,890 patients and characteristics of the studies are shown in 
Table 1. Most studies (59%) were published in 2012 or later. Of the 22 identified 
studies 19 reported HR for OS and three for cancer-specific survival. Two studies 
analyzed PLR as a continuous variable, twelve studies used a dichotomous cut-off for 
PLR (group 1) and eight defined three risk categories (group 2). All studies utilizing 
three risk categories reported a single HR, reflecting the average effect of comparing 
intermediate versus low and high versus intermediate risk (i.e. an increase of one risk 
category). After exclusion of the two studies analyzing PLR as a continuous variable 
(pooled HR for OS 1.01, 95% CI 1.00 – 1.01, P < 0.001) the main analysis was 
conducted using data from 20 studies comprising 12,754 patients. Inspection of the 
funnel plots did not reveal any evidence of publication bias (Supplementary Figure 1, 
available online). 
 
Overall survival 
 Overall, higher PLR was associated with worse survival.  Among studies of 
group 1 (median cut-off for PLR = 185) the pooled HR for survival for PLR above the 
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cut-off was 1.87 (95% CI 1.49 – 2.34, P < 0.001, Figure 2A). For studies of group 2 
(i.e. two cut-offs defining low, intermediate and high PLR, usually <150, 150-300, 
>300) HR for OS per risk category was 1.21 (95% CI 0.97 – 1.50, P = 0.10, Figure 
2B). There was statistically significant heterogeneity in both groups (group 1: 
Cochran Q P < 0.001, I2 = 65%; group 2: Cochran Q P < 0.001, I2 = 75%). In group 
1, heterogeneity was introduced by one outlying study with HR = 4.81 (17); exclusion 
of this study reduced I2 to 11% (P = 0.34) and changed the pooled estimate to 1.70 
(95% CI 1.47 – 1.95, P < 0.001). For group 2 no individual study could explain 
heterogeneity. 
 High PLR was associated with significantly worse survival for colorectal, 
gastro-esophageal, hepatocellular, pancreatic, and ovarian cancers in group 1 (HRs 
1.57, 1.84, 3.33, 2.43, 1.57, respectively) but not for breast cancer (Figure 3A). For 
group 2, PLR was associated with worse survival only for colorectal cancer (HR 2.02) 
but not for other disease sites (Figure 3B).  
 Overall, a prognostic role of PLR was observed for metastatic or mixed groups 
of patients (HR 2.03; 95% CI 1.55 - 2.65, P = 0.001 and HR 1.61; 95% CI 1.10 – 
2.37, P = 0.01 for group 1 and group 2, respectively) but only for patients with non-
metastatic disease when a dichotomous cut-off was used (HR 1.48; 95% CI 1.01 – 
2.17, P = 0.04 and HR 1.04; 95% CI 0.82 – 1.32, P = 0.73 for group 1 and group 2, 
respectively).  
In sensitivity analyses, higher values of HR were reported in full papers as 
compared with abstracts in group 1, but not in group 2. Further subgroup comparisons 
and sensitivity analyses are shown in Table 2. The scatter plot for the meta-regression 
is shown in Supplementary Figure 2, available online. Overall, studies with good 
quality reported higher HR for OS than those for poor quality studies. This effect was 
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observed both for studies reporting dichotomous risk groups (β = 0.537, P < 0.001) 
and for those reporting 3 risk groups (β = 0.147, P = 0.001). 
 
Comparison with Other Inflammatory Markers 
 The pooled HRs for PLR compared with other markers of inflammation, 
namely NLR, CRP, and GPS/mGPS were not statistically different (Table 3). Only 
two studies reported HRs for NLR and PLR from multivariable analyses. In one of 
these studies (18) both NLR and PLR retained statistical significance. In the second 
study NLR was not independently prognostic after adjustment for PLR. 
 
 
Discussion 
 
Several studies have considered the relationship between inflammatory 
markers and outcome of patients with solid tumors. Here, we used meta-analysis to 
combine twenty studies exploring the prognostic role of PLR in 12,754 patients with 
solid tumors. Most of these studies have been published since 2012, highlighting the 
recent interest in PLR as a potential prognostic marker. We found an association 
between elevated PLR and poor survival. In studies reporting a dichotomous cut-off 
for PLR this association was seen among several disease sites and both for metastatic 
and non-metastatic disease whereas it was less apparent for studies reporting three 
risk categories defined by two different cut-offs for PLR. Presumably, this at least in 
part is due to numerically lower hazard ratios that apply per higher risk category 
compared to use of single cut-offs. As the direction of effect is the same, it may be 
hypothesized that if binary cut-offs had been used in studies reporting three risk 
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groups, these may have reached statistically significance. Sensitivity analyses of type 
of publication and data collection did not change the overall result. 
Differences in hazard ratios were observed between cancer sites and may be 
the result of inflammation playing differing roles in different types of cancer. For 
example, strong links with systemic inflammation and elevated inflammatory markers 
(CRP and GPS) have been established in colorectal cancer (4). In the present analysis 
this is supported by a strong association between PLR and OS for this disease. In 
ovarian cancer, where we found a HR of 1.57, both thrombocytosis and elevated 
inflammatory markers have been linked to poor prognosis (4, 8).  
The mechanisms underlying the association of high PLR and poor outcome of 
cancer patients are poorly understood. Inflammatory cytokines and chemokines can 
be produced by both the tumor and associated host cells such as leukocytes and 
platelets, contributing to malignant progression (19). Indeed, we found the strongest 
association between PLR and survival in metastatic or mixed groups of patients when 
compared to study populations with loco-regional disease. While a variety of 
cytokines are implicated in the systemic inflammatory response, IL-6 acts to increase 
the synthesis of acute phase proteins, including CRP, and to decrease albumin 
production in the liver, the two elements encompassed by the Glasgow Prognostic 
Score (20). IL-6 also stimulates the differentiation of megakaryocytes to platelets and 
is involved in recruitment of neutrophils (21, 22). Several studies have shown that IL-
6 can stimulate thrombopoietin production and can lead to increases of platelet counts 
in cancer patients (23). In patients with ovarian cancer, high IL-6 level is an 
independent predictor of poor prognosis (8). Further, serum concentration of IL-6 has 
been shown to be increased in 13 different cancer types and has been associated with 
tumor stage and disease progression (22).  
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In an exploratory analysis we compared the relative prognostic impact of PLR 
with other markers of inflammation, namely NLR, CRP, and GPS/mGPS and did not 
find any of these to be a stronger prognostic marker then the others. In studies 
reporting HRs for both NLR and PLR, NLR was associated with a numerically higher 
HR for death in univariable analysis; this may be due to the more varied properties of 
neutrophils in comparison to platelets, such as the secretion of various cytokines (24-
27), but this difference did not reach statistical significance. Either CRP or 
GPS/mGPS might be stronger predictors of survival than PLR but data from only 2 
studies were available for comparison. Overall, it is likely that common mechanisms 
lead to concurrent elevation of multiple inflammatory factors.  
Limitations of this study include the fact that only summarized data rather 
than individual patient data could be used and that two studies were published only in 
abstract form and have not undergone rigorous peer review. Second, most studies 
(70%) provided only HRs from univariable analysis which could introduce a bias 
towards overestimation of the prognostic role of PLR, as HRs in multivariable 
analysis may have been non-significant due to inclusion in the multivariable model of 
other markers of systemic inflammation such as CRP, hypoalbuminemia, GPS, or 
NLR. We aimed to address such confounding by performing sensitivity analyses and 
did not find a significant difference between subgroups. Furthermore, studies not 
reporting hazard ratios or Kaplan Meier curves were excluded, potentially introducing 
further bias. Finally, we cannot exclude the possibility that non-malignant factors may 
have influenced the reported PLR. Authors of most studies included in our analysis 
explicitly excluded patients with infection and/or inflammatory conditions and some 
mentioned exclusion of patients with hypothyroidism, hyperthyroidism, temperature 
>37.2C, or patients on glucocorticoids or non-steroidal anti-inflammatory drugs. 
Furthermore, most studies reported that PLR was calculated from blood counts drawn 
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prior to actual treatment. Our meta-regression suggests that the effect size of PLR on 
OS was greater in studies with more comprehensive exclusion of non-malignant 
causes of inflammation. Therefore, it is possible that our inclusion of studies without 
robust control for confounders actually diluted the effect of PLR on outcome. 
To establish PLR as a prognostic marker, the clinical significance of this 
indicator must be further validated. The cut-off value must be established in one 
cohort of patients and tested in another and the number of patients in each group 
needs to be considered in the statistical analysis (28). With the use of patient level 
data, the overlap of outcomes between high and low risk of PLR must be considered. 
The differing results by cancer site and metastatic compared to locoregional disease 
reported here suggest that prognosis based on PLR may not be generalizable across 
differing patient groups.  
 In summary, this meta-analysis concludes that a high PLR is an independent 
factor associated with poorer overall survival in many solid tumors and is comparable 
to other established hematological markers of inflammation. As a cost-effective and 
readily available biomarker PLR may thus be useful in the clinical setting. 
Investigation of the addition of PLR to established prognostic scores to stratify 
patients in clinical trials is warranted. The selection of the most relevant marker of 
inflammation to indicate prognosis will require head to head comparisons. 
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Legends for figures 
 
Figure 1.  Selection of studies for analysis. 
 
 
Figure 2.  Main analysis of included studies. A. Group 1, dichotomized cut-offs for 
platelet to lymphocyte ratio (PLR); B. Group 2, two cut-offs for PLR. 
 
 
Figure 3. Prognostic impact of platelet to lymphocyte ratio (PLR) according to 
disease sites. A. Group 1, dichotomized cut-offs for PLR; B. Group 2, two cut-offs for 
PLR. 
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Table 1. Characteristics of included studies 
Reference Disease Stage PLR collected 
pre-treatment 
Patients with 
infection and/or 
inflammatory 
conditions 
excluded 
N Cut-off Outcome 
Aliustaoglu 2010 
(29) 
Gastric non-metastatic yes yes 168 160 OS 
Asher 2011 (30) Ovarian non-metastatic and 
metastatic 
yes yes 235 300 OS 
Azab 2013 (18) Breast non-metastatic and 
metastatic 
yes yes 437 185a OS 
Bhatti 2010 (31) Pancreatic non-metastatic yes yes 84 <100/100-
200/>200 
OS 
Carruthers 2012 
(32) 
Rectal non-metastatic yes nr 115 160 OS 
Cordiner 2011 (33) Breast non-metastatic nr nr 707 nrb CSS 
Dutta 2011 (34) Oesophageal non-metastatic yes yes 112 <150/150- CSS 
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300/>300 
Dutta 2012 (35) Gastric non-metastatic yes yes 120 <150/150-
300/>300 
CSS 
Fox 2013 (36) Renal non-metastatic and 
metastatic 
yes nr 362 195 OS 
He 2013 (37) Colorectal metastatic yes yes 243 150c OS 
Kinoshita 2012 
(17) 
Hepatocellular non-metastatic and 
metastatic 
yes yes 150 150 OS 
Kwon 2012 (38) Colorectal non-metastatic and 
metastatic 
yes yes 200 <150/150-
300/>300 
OS 
Lee 2012 (39) Colorectal metastatic yes nr 60 <150/150-
300/>300 
OS 
Pinato 2012 (40) Hepatocellular non-metastatic and 
metastatic 
yes† yes 112 300 OS 
Pinato 2012 (41) Mesothelioma non-metastatic and 
metastatic 
yes† yes 171 300 OS 
Proctor 2011 (42) Various non-metastatic  no‡ no 8759 <150/150-
300/>300 
OS  
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Raungkaewmanee 
2012 (43) 
Ovarian non-metastatic and 
metastatic 
yes yes 166 200 OS 
Sakka 2009 (44) Pancreatic/Periampullar
y neuroendocrine 
non-metastatic yes nr 32 Continuous OS 
Smith 2008 (45) Ampullary non-metastatic yes nr 52 160 OS 
Smith 2009 (46) Pancreatic non-metastatic yes nr 104 Continuous OS 
Wang 2012 (47) Gastric non-metastatic yes nr 324 <150/150-
300/>300 
OS 
Wang 2012 (48) Pancreatic non-metastatic and 
metastatic 
yes yes 177 <150/150-
300/>300 
OS 
† (D. J. Pinato; personal communication), ‡ within two years following diagnosis of cancer, a 4th quartile versus others, b considered dichotomous, c 
150 versus 150-300. 
 
CSS, cancer specific survival; nr, not reported; OS, overall survival; PLR, platelet to lymphocyte ratio.    
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Table 2. Subgroup and Sensitivity Analyses 
Group 1 (dichotomous cut-off) Group 2 (three categories) 
N HR 95% CI P  P † N HR 95% CI P  P † 
Disease Stage     
Non-metastatic 4 1.48 1.01-2.17 0.04 
0.19 
5 1.04 0.82-1.32 0.73 
0.06 Metastatic/ Mixed 8 2.03 1.55-2.65 <0.01 3 1.61 1.10-2.37 0.01 
Article Type     
Abstract 1 0.96 0.58-1.59 0.87 
0.01 
1 2.09 1.23-3.55 0.01 
0.04 Full paper 11 1.98 1.60-2.46 <0.01 7 1.13 0.92-1.40 0.25 
Study Type     
Prospective 3 1.78 1.49-2.14 <0.01 
0.79 
1 1.95 1.16-3.29 0.01 
0.06 Retrospective 9 1.88 1.35-2.61 <0.01 7 1.14 0.92-1.42 0.23 
Variable type     
Multivariable 3 1.90 1.31-2.75 <0.01 
0.95 
3 1.95 1.50-2.55 <0.01 
<0.01Univariable 9 1.87 1.41-2.47 <0.01 5 0.98 0.91-1.05 0.54 
Hazard Ratio     
Reported in study 8  1.67 1.38-2.04  <0.01  0.25 8 1.21  0.97-1.50  0.10 NA 
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Estimated from survival curves 4  2.41 1.33-4.38  <0.01  0 
ROC curve     
Considered 2 2.65 0.80-8.83 0.11 
0.48 
1 1.89 1.30-2.75 <0.01 
0.02   Not considered 10 1.71 1.47-1.99 <0.01 7 1.11 0.91-1.36 0.30 
 P-value for HR; † P-value for subgroup difference.  
CI, confidence interval; HR, hazard ratio; ROC, receiver operator characteristic (C-index). 
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Table 3. Comparison of Relative Risk of HR between PLR, CRP and GPS  (group 1 only) 
 
Studies (N) 
Pooled HR 
for PLR 
95% CI 
Pooled HR 
for 
comparator 
95% CI 
Subgroup 
Difference 
PLR vs. NLR (multivariablea) 2 2.13 1.36-3.33 1.76 0.44-7.13 0.800 
PLR vs. NLR (univariablea) 7 1.76 1.42-2.18 2.20 1.52-3.20 0.310 
PLR vs. CRP (univariablea) 2 1.66 1.20-2.29 1.96 1.43-2.68 0.470 
PLR vs. GPS/mGPS (univariablea) 2 1.66 1.20-2.29 2.14 1.55-2.95 0.280 
a Hazard Ratio (HR) derived from univariable and multivariable models, respectively. 
CI, confidence interval; CRP, C-reactive protein; GPS, Glasgow Prognostic score; mGPS, modified GPS; NLR, neutrophil to 
lymphocyte ratio; PLR, platelet to lymphocyte ratio. 
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